CRINETICS PHARMACEUTICALS IN
CRNXNASDAQ🏆 #898 by market capEarnings Nov 5US Equity
$84.48▲ $0.12 (+0.14%)
Live1h▲ 0.0%
24h▲ 0.1%
7d▲ 0.5%
14d▲ 0.7%
30d▲ 1.0%
1y▲ 196.2%
🏦Market Cap
$8.95B
Small Cap
📈Revenue Growth (YoY)
+640.7%
High Growth
📊Gross Margin
99.2%
High
💵FCF Margin
-1008.6%
Thin
⚖️P/S Ratio
212.4x
Expensive
Otter Score
55
Weak
📊
Analyst Ratings
Price
$84.48
Total
21
Raised
1
Lowered
8
Avg PT
$84.86
H / L
$85 / $84
| Institution | Action | Rating | Date |
|---|---|---|---|
UBS | Downgraded | Buy → Neutral | 2026-07-28 |
Evercore ISI Group | Downgraded | Outperform → In Line | 2026-07-08 |
TD Cowen | Downgraded | Buy → Hold | 2026-07-08 |
Oppenheimer | Downgraded | Outperform → Perform | 2026-07-07 |
Cantor Fitzgerald | Downgraded | Overweight → Neutral | 2026-07-07 |
Baird | Reiterated | Outperform | 2026-07-07 |
HC Wainwright & Co. | Downgraded | Buy → Neutral | 2026-07-07 |
Jones Trading | Downgraded | Buy → Hold | 2026-07-07 |
Jefferies | Downgraded | Buy → Hold | 2026-07-07 |
Citizens | Reiterated | Market Outperform | 2026-06-11 |
Goldman Sachs | Upgraded | Neutral → Buy | 2026-01-12 |
Morgan Stanley | Reiterated | Overweight | 2026-01-06 |
Leerink Partners | Reiterated | Outperform | 2025-09-29 |
JMP Securities | Reiterated | Market Outperform | 2025-09-26 |
JP Morgan | Reiterated | Overweight | 2025-09-24 |
Citizens Capital Markets | Reiterated | Market Outperform | 2025-02-28 |
Citigroup | Reiterated | Buy | 2024-11-14 |
Piper Sandler | Reiterated | Overweight | 2024-07-02 |
JonesTrading | Reiterated | Buy | 2024-03-20 |
HC Wainwright& Co. | Reiterated | Buy | 2024-03-19 |
SVB Leerink | Reiterated | Outperform | 2022-05-26 |
One row per institution, most recent rating